Pentavalent Market Expansion Is Opening New Pathways For Strategic Investment
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Pentavalent Market Growth Potential: How Will Market Size Change Through 2030?
The pentavalent market has experienced consistent expansion in recent times, with its value projected to increase from $2.7 billion in 2025 to $2.83 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.6%. This upward trend during the historical period was driven by several factors, including higher infant mortality rates, restricted availability of vaccines, a significant occurrence of rotavirus infections, government-led immunization programs, and global public health campaigns.
In the coming years, the pentavalent market is projected to experience steady expansion, reaching a valuation of $3.39 billion by 2030, with a compound annual growth rate (CAGR) of 4.7%. This anticipated growth during the forecast period is driven by factors such as advancements in vaccine formulation technology, rising healthcare spending, the broadening of immunization initiatives in developing nations, collaborations among pharmaceutical companies, and the adoption of digital tracking systems for monitoring vaccine coverage. Key trends shaping this period include a rise in infant immunization programs, government investment in vaccine research, enhancements to public health infrastructure, greater awareness about rotavirus prevention, and improvements in cold chain logistics.
Download A Free Sample Report For Comprehensive Market Insights:
Pentavalent Market Expansion Supported By Key Demand Factors
An increasing number of diphtheria cases is anticipated to drive the expansion of the pentavalent market in the coming period. Diphtheria, a highly contagious and severe infectious disease, is caused by the bacterium Corynebacterium diphtheriae. This illness can lead to significant challenges with eating and breathing, along with the potential for skin ulcers. The pentavalent vaccine, administered in a three-dose immunization schedule, protects children against diphtheria, and consequently, the growing incidence of this disease has heightened demand for the vaccine. For example, in July 2025, the European Centre for Disease Prevention and Control (a government agency based in Europe) reported that a total of 126 laboratory-confirmed cases of C. diphtheriae ST574 have been identified across Germany, with 55 cases in 2022, 49 in 2023, 18 in 2024, and at least 4 in 2025. Hence, the rising prevalence of diphtheria is fueling the growth of the pentavalent market.
The pentavalent market is expected to be propelled forward by rising healthcare expenditure in the near future. Healthcare expenditure represents the total financial and other resources dedicated to delivering healthcare services over a given period. In relation to pentavalent vaccines, this expenditure encompasses the funds allocated for developing, manufacturing, distributing, and administering vaccines that shield against five distinct targeted diseases. For instance, in December 2024, the Centers for Medicare & Medicaid Services (a U.S. agency overseeing Medicare and Medicaid programs) noted that American healthcare spending rose by 7.5% in 2023, reaching $4.9 trillion, which equates to roughly $14,570 per person. Therefore, the increase in healthcare expenditure is fostering growth in the pentavalent market.
Pentavalent Market Segment Analysis: What Are The Major Market Categories?
The pentavalent market covered in this report is segmented –
1) By Type: Pentavalent Vaccines (DTP-HepB-Hib combination), Other Combination Vaccines
2) By Formulation Type: Lyophilized, Liquid
3) By Application: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Pentavalent Vaccines (DTP-HepB-Hib combination): DTP-HepB-Hib (Whole Cell), DTP-HepB-Hib (Acellular)
2) By Other Combination Vaccines: Hexavalent Vaccines
Pentavalent Market Growth Trends Influencing Competitive Dynamics
Key industry players in the pentavalent market are concentrating their efforts on advancing innovative products, particularly pentavalent immunization vaccines. These vaccines represent a type of combination immunization designed to guard against five distinct illnesses. As an example, in October 2023, Pfizer, a pharmaceutical company headquartered in the United States, received FDA clearance for its pentavalent vaccine, named ‘Penbraya’. This vaccine stands out as the first and only pentavalent option that offers defense against the five main meningococcal serogroups—A, B, C, W-135, and Y—for individuals aged 10 to 25 years. Penbraya is formulated by combining components from the Trumenba meningococcal group B vaccine with the Nimenrix conjugate vaccine targeting meningococcal groups A, C, W-135, and Y. Research has demonstrated Penbraya’s effectiveness in shielding against these five meningococcal serogroups, which are behind the vast majority of global instances of invasive meningococcal disease.
Pentavalent Market Leading Companies Driving Competitive Growth
Major companies operating in the pentavalent market are Pfizer Inc., Merck & Co Inc., Sanofi SA, GlaxoSmithKline plc, Shandong Xinhua Pharmaceutical Company Limited, PT Bio Farma (Persero), Shantha Biotechnics Limited, Biological E. Limited, Serum Institute of India Private Limited, Indian Immunologicals Limited, Incepta Pharmaceuticals Limited, Shanghai Institute of Biological Products Co Ltd., Changchun Changsheng Biotechnology Co Ltd., Adimmune Corporation, AJ Vaccines, Albert David Limited, PanGen Biotech Inc., Bharat Biotech International Limited, Vacsera Ltd., Pasteur Institute of India, Zydus Cadila Healthcare Limited, EuBiologics Co Ltd.
Access The Complete Pentavalent Market Report:
Pentavalent Market Leading Geography: Which Region Generates The Most Revenue?
Asia-Pacific was the largest region in the pentavalent market in 2025. The regions covered in the pentavalent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
